Treatment with the PPARγ agonist rosiglitazone downregulates interleukin-1 receptor antagonist in individuals with metabolic syndrome

European Journal of Endocrinology

Volumn 162, Issue 2, 2010, Pages 267-273

  Halvorsen, Bente ^a,b   Heggen, Eli ^a,b   Ueland, Thor ^a,b   Smith, Camilla ^a,b   Sandberg, Wiggo J ^a,b   Damås, Jan K ^a   Otterdal, Kari ^a,b   Tonstad, Serena ^a,b   Aukrust, På L ^a,b  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; ROSIGLITAZONE; URIC ACID; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOWN REGULATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; EDEMA; ERYTHROCYTE COUNT; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; INFLAMMATION; LEG CRAMP; MALE; METABOLIC SYNDROME X; MONOCYTE; PITTING EDEMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; AGED; DRUG POTENTIATION; FOLLOW UP; IMMUNOLOGY; METABOLISM; MIDDLE AGED;

ADULT; AGED; BIOLOGICAL MARKERS; CROSS-OVER STUDIES; DOWN-REGULATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PPAR GAMMA; THIAZOLIDINEDIONES;

EID: 75149116312     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-09-0706     Document Type: Article

References (39)

1. Jiamsripong P, Mookadam M, Alharthi MS, Khandheria BK & Mookadam F. The metabolic syndrome and cardiovascular disease: part 2. Preventive Cardiology 2008 11 223-229.
2. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. New England Journal of Medicine 2005 352 1685-1695.
3. Sjoholm A & Nystrom T. Endothelial inflammation in insulin resistance. Lancet 2005 365 610-612.
4. Jacobs M, van Greevenbroek MM, van der Kallen CJ, Ferreira I, Blaak EE, Feskens EJ, Jansen EH, Schalkwijk CG & Stehouwer CD. Low-grade inflammation can partly explain the association between the metabolic syndrome and either coronary artery disease or severity of peripheral arterial disease: the CODAM study. European Journal of Clinical Investigation 2009 39 437-444.
5. Rabe K, Lehrke M, Parhofer KG & Broedl UC. Adipokines and insulin resistance. Molecular Medicine 2008 14 741-751.
6. Smith SC Jr. Multiple risk factors for cardiovascular disease and diabetes mellitus. American Journal of Medicine 2007 120 S3-S11.
7. Yki-Jarvinen H. Thiazolidinediones. New England Journal of Medicine 2004 351 1106-1118.
8. Quinn CE, Hamilton PK, Lockhart CJ & McVeigh GE. Thiazolidinediones: effects on insulin resistance and the cardiovascular system. British Journal of Pharmacology 2008 153 636-645.
9. Hetzel J, Balletshofer B, Rittig K, Walcher D, Kratzer W, Hombach V, Haring HU, Koenig W & Marx N. Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers. Arteriosclerosis, Thrombosis, and Vascular Biology 2005 25 1804-1809.
10. Duan SZ, Usher MG & Mortensen RM. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature. Circulation Research 2008 102 283-294.
11. Marx N, Imhof A, Froehlich J, Siam L, Ittner J, Wierse G, Schmidt A, Maerz W, Hombach V & Koenig W. Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation 2003 107 1954-1957.
12. Kalaitzidis RG, Sarafidis PA & Bakris GL. Effects of thiazolidinediones beyond glycaemic control. Current Pharmaceutical Design 2009 15 529-536.
13. Aukrust P, Berge RK, Muller F, Ueland PM, Svardal AM & Froland SS. Elevated plasma levels of reduced homocysteine in common variable immunodeficiency - a marker of enhanced oxidative stress. European Journal of Clinical Investigation 1997 27 723-730.
14. Holven KB, Scholz H, Halvorsen B, Aukrust P, Ose L & Nenseter MS. Hyperhomocysteinemic subjects have enhanced expression of lectin-like oxidized LDL receptor-1 in mononuclear cells. Journal of Nutrition 2003 133 3588-3591.
15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF & Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 412-419.
16. Aukrust P, Bjornsen S, Lunden B, Otterdal K, Ng EC, Ameln W, Ueland T, Muller F, Solum NO, Brosstad F & Frøland SS. Persistently elevated levels of von Willebrand factor antigen in HIV infection. Downregulation during highly active antiretroviral therapy. Thrombosis and Haemostasis 2000 84 183-187.
17. Arora S, Aukrust P, Ueland T, Broch K, Simonsen S, Gude E, Fiane AE, Geiran O, Wergeland R, Andreassen AK & Gullestad L. Elevated serum uric acid levels following heart transplantation predict all-cause and cardiac mortality. European Journal of Heart Failure 2009 10 1005-1013.
18. Charo IF & Taubman MB. Chemokines in the pathogenesis of vascular disease. Circulation Research 2004 95 858-866.
19. Granowitz EV, Santos AA, Poutsiaka DD, Cannon JG, Wilmore DW, Wolff SM & Dinarello CA. Production of interleukin-1-receptor antagonist during experimental endotoxaemia. Lancet 1991 338 1423-1424.
20. Waehre T, Yndestad A, Smith C, Haug T, Tunheim SH, Gullestad L, Froland SS, Semb AG, Aukrust P & Damas JK. Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors. Circulation 2004 109 1966-1972.
21. Giannini S, Serio M & Galli A. Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity. Journal of Endocrinological Investigation 2004 27 982-991.
22. Meisner F, Walcher D, Gizard F, Kapfer X, Huber R, Noak A, Sunder-Plassmann L, Bach H, Haug C, Bachem M, Stojakovic T, Marz W, Hombach V, Koenig W, Staels B & Marx N. Effect of rosiglitazone treatment on plaque inflammation and collagen content in nondiabetic patients: data from a randomized placebo-controlled trial. Arteriosclerosis, Thrombosis, and Vascular Biology 2006 26 845-850.
23. Kim HJ, Kang ES, Kim DJ, Kim SH, Ahn CW, Cha BS, Nam M, Chung CH, Lee KW, Nam CM & Lee HC. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus. Clinical Endocrinology 2007 66 282-289.
24. Arend WP, Malyak M, Guthridge CJ & Gabay C. Interleukin-1 receptor antagonist: role in biology. Annual Review of Immunology 1998 16 27-55.
25. Dinarello CA. Interleukin-1beta and the autoinflammatory diseases. New England Journal of Medicine 2009 360 2467-2470.
26. Fearon WF & Fearon DT. Inflammation and cardiovascular disease: role of the interleukin-1 receptor antagonist. Circulation 2008 117 2577-2579.
27. Chamberlain J, Francis S, Brookes Z, Shaw G, Graham D, Alp NJ, Dower S & Crossman DC. Interleukin-1 regulates multiple atherogenic mechanisms in response to fat feeding. PLoS One 2009 4 e5073.
28. Dinarello CA. Blocking IL-1 in systemic inflammation. Journal of Experimental Medicine 2005 201 1355-1359.
29. Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, Seifert B, Mandrup-Poulsen T & Donath MY. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. New England Journal of Medicine 2007 356 1517-1526.
30. Carter KW, Hung J, Powell BL, Wiltshire S, Foo BT, Leow YC, McQuillan BM, Jennens M, McCaskie PA, Thompson PL, Beilby JP & Palmer LJ. Association of interleukin-1 gene polymorphisms with central obesity and metabolic syndrome in a coronary heart disease population. Human Genetics 2008 124 199-206.
31. Juge-Aubry CE, Somm E, Giusti V, Pernin A, Chicheportiche R, Verdumo C, Rohner-Jeanrenaud F, Burger D, Dayer JM & Meier CA. Adipose tissue is a major source of interleukin-1 receptor antagonist: upregulation in obesity and inflammation. Diabetes 2003 52 1104-1110.
32. Cartier A, Bergeron J, Poirier P, Almeras N, Tremblay A, Lemieux I & Despres JP. Increased plasma interleukin-1 receptor antagonist levels in men with visceral obesity. Annals of Medicine 2009. In Press DOI: 10.1080/07853890903022801.
33. Nissen SE & Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. New England Journal of Medicine 2007 356 2457-2471.
34. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M & McMurray JJ. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009 373 2125-2135.
35. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M & McMurray JJ. Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. New England Journal of Medicine 2007 357 28-38.
36. Meier CA, Chicheportiche R, Juge-Aubry CE, Dreyer MG & Dayer JM. Regulation of the interleukin-1 receptor antagonist in THP-1 cells by ligands of the peroxisome proliferator-activated receptor gamma. Cytokine 2002 18 320-328.
37. Moulin D, Bianchi A, Boyault S, Sebillaud S, Koufany M, Francois M, Netter P, Jouzeau JY & Terlain B. Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1beta-stimulated rat synovial fibroblasts via a peroxisome proliferator-activated receptor beta/delta-dependent mechanism. Arthritis and Rheumatism 2005 52 759-769.
38. Derosa G & Salvadeo SA. Pioglitazone and rosiglitazone: effects of treatment with a thiazolidinedione on lipids and non conventional cardiovascular risk factors. Current Clinical Pharmacology 2008 3 77-84.
39. Rizzo M, Christ ER, Rini GB, Spinas GA & Berneis K. The differential effects of thiazolidindiones on atherogenic dyslipidemia in type 2 diabetes: what is the clinical significance? Expert Opinion on Pharmacotherapy 2008 9 2295-2303.